AFINITOR Drug Patent Profile

When do Afinitor patents expire, and what generic alternatives are available?

Afinitor is a drug marketed by Novartis and Novartis Pharm and is included in two NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and twenty-nine patent family members in thirty-one countries.

The generic ingredient in AFINITOR is everolimus. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the everolimus profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Afinitor

A generic version of AFINITOR was approved as everolimus by HIKMA on April 12^th, 2018.

Summary for AFINITOR

International Patents:	229
US Patents:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	41
Clinical Trials:	182
Patent Applications:	2,412
Drug Prices:	Drug price information for AFINITOR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AFINITOR
What excipients (inactive ingredients) are in AFINITOR?	AFINITOR excipients list
DailyMed Link:	AFINITOR at DailyMed

See drug prices for AFINITOR

Recent Clinical Trials for AFINITOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Texas Health Science Center at San Antonio	EARLY_PHASE1
National Institute on Aging (NIA)	EARLY_PHASE1
Fudan University	Phase 3

See all AFINITOR clinical trials

Pharmacology for AFINITOR

Drug Class	Kinase Inhibitor mTOR Inhibitor Immunosuppressant
Mechanism of Action	Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors Protein Kinase Inhibitors mTOR Inhibitors
Physiological Effect	Decreased Immunologic Activity

Paragraph IV (Patent) Challenges for AFINITOR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AFINITOR	Tablets	everolimus	2.5 mg, 5 mg, and 7.5 mg	022334	1	2014-12-10
AFINITOR	Tablets	everolimus	10 mg	022334	1	2014-06-18

US Patents and Regulatory Information for AFINITOR

AFINITOR is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-003	Jul 9, 2010	AB	RX	Yes	No	9,006,224
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-002	Mar 30, 2009	AB	RX	Yes	No	9,006,224
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-001	Mar 30, 2009	AB	RX	Yes	Yes	8,410,131*PED				Y
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-002	Mar 30, 2009	AB	RX	Yes	No	8,410,131*PED				Y

Expired US Patents for AFINITOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-003	Jul 9, 2010	7,741,338
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-001	Mar 30, 2009	7,741,338
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-004	Mar 30, 2012	7,741,338
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-002	Mar 30, 2009	7,741,338

EU/EMA Drug Approvals for AFINITOR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Afinitor	everolimus	EMEA/H/C/001038Hormone-receptor-positive advanced breast cancerAfinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.Neuroendocrine tumours of pancreatic originAfinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.Neuroendocrine tumours of gastrointestinal or lung originAfinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.Renal-cell carcinomaAfinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.	Authorised	no	no	no	2009-08-02
Novartis Europharm Limited	Votubia	everolimus	EMEA/H/C/002311Renal angiomyolipoma associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.The evidence is based on analysis of change in sum of angiomyolipoma volume.Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery.The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease‑related symptoms, has not been demonstrated.	Authorised	no	no	no	2011-09-02

International Patents for AFINITOR

See the table below for patents covering AFINITOR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	173736
Austria	272063
Australia	4819293
Australia	676198

Supplementary Protection Certificates for AFINITOR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0663916	300154	Netherlands		PRODUCT NAME: EVEROLIMUSUM; NATIONAL REGISTRATION NO/DATE: RVG 30041 20040610; FIRST REGISTRATION: SE 18690 20030718
0663916	91104	Luxembourg		91104, EXPIRES: 20180718
0663916	CA 2004 00020	Denmark		PRODUCT NAME: EVEROLIMUS
0663916	SZ 14/2004	Austria		PRODUCT NAME: EVEROLIMUS (40-0-(2-HYDROXY)ETYHL RAPAMYCIN)

AFINITOR (everolimus) Market Dynamics and Financial Trajectory: Exclusivity, Generic Risk, Competition, and Revenue Outlook

Last updated: July 21, 2026

Executive summary: AFINITOR (everolimus) remains a multi-indication oncology and immunology franchise anchored by mTOR inhibition, with sustained U.S. and ex-U.S. demand supported by label breadth (e.g., HR+/HER2- advanced breast cancer; renal cell carcinoma; neuroendocrine tumors). The revenue trajectory is shaped by (1) ongoing patent and regulatory exclusivity layering, (2) competitive pressure from next-line targeted therapies and broader immuno-oncology adoption, (3) pricing and reimbursement dynamics, and (4) erosion risk as select formulations and methods-of-use approach key expiration windows. Financial performance is also sensitive to trial-driven shifts in standard-of-care positioning, including sequencing versus newer agents.

---

What is the AFINITOR (everolimus) commercial profile by indication and geography?

Answer: AFINITOR’s commercial profile is driven by a concentrated set of oncology indications where mTOR inhibition is integrated into treatment pathways, with additional resilience from long-term use patterns and combination regimens. Geography matters most through pricing, tendering, and uptake in European national formularies, while U.S. dynamics are dominated by reimbursement policies and competitive access.

Which indications have historically carried AFINITOR revenue?

High-contribution indications for everolimus in the U.S. include:

• Breast cancer (HR+/HER2-): AFINITOR plus exemestane in advanced disease following progression on aromatase inhibitor therapy.
• Renal cell carcinoma (RCC): AFINITOR in combination or monotherapy settings depending on line of therapy and local label application.
• Neuroendocrine tumors (NETs): AFINITOR for progressive, well-differentiated, nonfunctional or functional pancreatic NETs and other NET subsets depending on the label year and country.
• Other oncology settings: country-specific label scope.

Commercial implication: Even when absolute patient counts stay stable, AFINITOR revenue is sensitive to:

• shifts in sequencing (e.g., earlier use of newer kinase or immunotherapy regimens),
• duration of therapy (dose intensity and toxicity-driven discontinuation),
• and substitution by later-line agents with better PFS or OS data.

How do geography and access impact AFINITOR sales?

• U.S.: pricing pressure and payer scrutiny increase as competitive offerings expand and when AFINITOR faces generic and/or authorized generic competition in any formulation.
• EU5 and other major markets: national reimbursement and tendering cycles can cause step-function changes in net sales even without label restriction.

---

How do AFINITOR sales move with pricing, reimbursement, and product mix?

Answer: Revenue changes are typically most responsive to net price and mix across indications rather than wholesale volume alone, because the drug is used in oncology settings with strong payer involvement.

Key drivers of net sales volatility

• WAC-to-net discounts: oncology biologics and specialty drugs increasingly face aggressive managed-care discounting.
• Indication mix: shifts between HR+/HER2- breast cancer, RCC, and NET can change weighted average realized price.
• Dose and adherence: discontinuation due to stomatitis, rash, pneumonitis, hyperglycemia, or cytopenias reduces effective treatment duration and revenue per patient.

What product formats affect revenue stability?

AFINITOR is a specialty oral solid product (tablet strength varies by market and period). Revenue durability tends to be stronger when:

• the dosing schedule supports stable prescribing, and
• manufacturing supply is consistent enough to avoid disruptions.

---

When does exclusivity end for AFINITOR, and what does that mean for sales erosion risk?

Answer: The generic and authorized generic risk for AFINITOR is tied to the expiration of Orange Book-listed patents and any pediatric exclusivity/market exclusivity that may extend key windows. As those layers fall away, erosion risk rises fastest where patents are weakest or where there are fewer formulation barriers.

How exclusivity layering typically governs the AFINITOR curve

For branded specialty oncology drugs, sales often show:

• a stable-to-gradual decline during the “last protected” period for major indications,
• a faster step-down around the first market entry (generic or authorized generic),
• then a plateau driven by payer switching friction and clinician inertia.

Generic entry risk categories for everolimus

• Composition-of-matter type expiry (core active ingredient protection).
• Formulation and method-of-use expiry (often later and more litigated).
• Combination regimen claims tied to specific therapeutic standards (jurisdiction-specific).

Commercial implication: Sales erosion speed depends on whether generic entry is blocked by remaining formulation or method-of-use patents and whether FDA approval includes carve-outs for protected indications.

---

How many patents protect AFINITOR in the U.S., and which claim types matter most?

Answer: The U.S. patent estate for everolimus listed in the Orange Book typically includes a mix of composition, formulation, and method-of-use patents. For market dynamics, the method-of-use and formulation layers are the practical gatekeepers because they can still block label carve-outs even after composition expiry.

Claim types that most affect generic launch timing

1. Formulation patents (e.g., tablets with specific release characteristics, excipient systems, or manufacturing/process parameters).
2. Method-of-use patents (e.g., dosing regimens in a specific disease state, including combinations such as everolimus plus endocrine therapy).
3. Specific strength and dosing form claims (can limit automatic substitutability).

How does patent scope translate into FDA labeling and launch permissions?

If remaining patents cover:

• a major indication, generics may launch only for non-covered indications, or
• use labeling restrictions and “skinny label” carve-outs.

Sales impact: AFINITOR can lose share even with partial carve-outs because prescribers may shift to the easiest-to-prescribe label indications for which generics are allowed.

---

What Paragraph IV challenges exist for AFINITOR, and what outcomes drive the generic timeline?

Answer: The generic timeline is determined by the filing of Abbreviated New Drug Applications with a Paragraph IV certification against Orange Book-listed patents, and by subsequent litigation or settlements that trigger forfeiture of 180-day exclusivity or launch delays.

What litigation outcomes usually determine market timing

• Injunctions from successful brand motions can delay entry.
• Settlement agreements often create phased entry dates, sometimes limited to certain strengths or indications.
• Court outcomes can shorten or extend the effective exclusivity period beyond the statutory expiry schedule.

Market dynamic: authorized generic and “switching friction”

Even where generics launch, uptake is shaped by:

• patient assistance program arrangements,
• wholesaler channel stocking patterns,
• and pharmacy benefit manager switching rules.

---

What settlement agreements and launch pathways have shaped the everolimus competitive landscape?

Answer: Settlements in specialty drugs are frequently designed to resolve patent disputes while preserving brand revenue for a defined interval. The primary commercial questions are:

• launch date,
• scope of labeling carve-outs,
• and whether an authorized generic appears at the same time.

How settlements change the revenue curve

A settlement that permits generic entry quickly tends to produce:

• steeper revenue decline,
• shorter remaining runway for brand price concessions,
• and higher competitive discounting.

A settlement that delays entry or restricts scope tends to produce:

• gradual erosion,
• sustained payer coverage in protected indications,
• more time to shift mix toward remaining protected uses.

---

How strong is AFINITOR’s patent estate versus competing mTOR inhibitors?

Answer: AFINITOR’s strength is typically measured by the breadth and duration of Orange Book-listed patents across formulation and method-of-use claims. Competitive pressure is also driven by whether other mTOR inhibitors (or next-line oncology regimens) can displace everolimus in clinical practice.

What defines competitive patent advantage in mTOR space?

• Label coverage duration for major indications.
• Formulation and dosing patents that complicate bioequivalence or interchange.
• Method-of-use claims that restrict generic labeling.

Commercial implication: Even if a competitor has faster patent clearance, AFINITOR can retain share if it has a durable clinical position and established treatment protocols.

---

How does AFINITOR compare with alternative therapies in HR+/HER2- breast cancer?

Answer: In HR+/HER2- advanced breast cancer, everolimus-based therapy competes with endocrine strategies enhanced by newer targeted agents and with evolving immuno-oncology approaches in specific subpopulations.

Key decision points that affect AFINITOR prescribing

• prior aromatase inhibitor exposure,
• progression tempo and disease burden,
• toxicity tolerability and comorbidity profile (diabetes, pneumonitis risk),
• and local guideline adoption.

Revenue impact: Even where AFINITOR retains label, real-world use can shift if newer options offer better tolerability or sequencing advantage.

---

How does AFINITOR compete in renal cell carcinoma (RCC) and neuroendocrine tumors (NETs)?

Answer: In RCC and NETs, AFINITOR competes in later-line settings and/or combination frameworks with targeted therapies and, increasingly, regimen choices optimized around immunotherapy.

What drives share changes in RCC and NETs

• preference for agents with improved survival endpoints in specific risk groups,
• adoption of combination immunotherapy standards,
• and payer coverage policies tied to guideline concordance.

Commercial implication: Where treatment paradigms shift away from mTOR inhibition, revenue can decline even before generics enter.

---

What regulatory milestones and FDA status shape AFINITOR’s market access?

Answer: FDA approval status influences market access via label scope, switching guidance, and post-marketing commitments that can affect supply continuity and clinician comfort.

Key regulatory factors affecting commercial performance

• label expansions or narrowing over time,
• safety communication updates that affect persistence rates,
• and interactions with generic approval pathways through patent listings and certifications.

Market dynamic: A drug can maintain high sales until generic entry, but safety-driven discontinuation can create longer, slower erosion even under patent protection.

---

Which companies are positioned to challenge AFINITOR with generics or biosimilars?

Answer: For everolimus, the primary competitive threat is generic small-molecule entry, not biosimilars. Generic manufacturers can be positioned to launch via ANDA pathways depending on patent carve-outs and litigation outcomes.

What to monitor for competitive timing

• ANDA submissions with Paragraph IV certifications,
• district court dockets and motions related to Orange Book patents,
• settlement press releases and court orders specifying launch dates and scope.

Commercial implication: Multiple filers typically reduce brand negotiating leverage as 180-day exclusivity gets contested.

---

What manufacturing and IP barriers could delay AFINITOR generic substitution?

Answer: Barriers usually come from:

• remaining formulation or process patents,
• strength-specific protections,
• and potential supply or quality-system constraints for complex oral dosage strengths.

Market dynamic: supply stability

Generic substitution depends on:

• reliable scale-up,
• consistent dissolution and bioequivalence,
• and packaging that aligns with pharmacy ordering patterns.

Even with legal clearance, supply constraints can preserve short-term brand revenue.

---

Revenue exposure scenarios for AFINITOR: base, downside, and upside

Answer: AFINITOR’s revenue is exposed to two independent forces: patent-based substitution and clinical standard-of-care displacement. Scenario planning should treat those as separate legs.

Base case: slower erosion until near-term label carve-outs

• continued use in protected indications,
• gradual payer discounting,
• generic entry limited by remaining patent barriers or phased settlements.

Downside case: rapid generic entry with meaningful label scope

• faster substitution across multiple high-contribution indications,
• authorized generic pressure (if timed with generic entry),
• increased payer switching due to lower net price.

Upside case: delayed substitution plus mix shift toward resilient indications

• litigation delays and settlement deferrals,
• incremental uptake in indications with fewer competing regimens,
• improved persistence due to safety management improvements.

---

Key Takeaways

• AFINITOR’s market dynamics are governed by the interplay of indication mix, payer net pricing, and therapeutic sequencing versus newer oncology standards.
• Exclusivity and Orange Book patent layering determine how quickly substitution accelerates after first market entry.
• For everolimus, the competitive threat is small-molecule generics (not biosimilars), with timing driven by Paragraph IV challenges and litigation/settlement outcomes.
• Even absent generic entry, standard-of-care displacement and toxicity-driven persistence can create gradual revenue erosion.
• The steepest revenue declines typically align with label-scope-friendly generic launches, especially when an authorized generic appears and broadens payer switching.

---

FAQs

1) What filings most directly predict AFINITOR generic launch dates?
ANDA Paragraph IV certifications tied to Orange Book-listed everolimus patents, plus litigation dockets and settlement terms specifying launch scope.

2) Can generic everolimus launch for only some AFINITOR indications?
Yes, where remaining patents support label carve-outs, generics can launch with restricted labeling.

3) What safety-related factors most influence AFINITOR real-world persistence?
Common discontinuation drivers include stomatitis, noninfectious pneumonitis, rash, hyperglycemia, and cytopenias, which can reduce treatment duration.

4) How do pricing and rebate changes affect AFINITOR net sales more than unit volume?
Specialty oncology drugs often see net price volatility from managed care rebates, tendering, and payer-specific formularies even when prescription volume is stable.

5) What competitive factor matters more for AFINITOR than patent expiry?
Therapeutic sequencing in RCC, NETs, and HR+/HER2- breast cancer can shift real-world use ahead of generic entry, reducing revenue even under continued brand exclusivity.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Approval Package: Afinitor (everolimus). U.S. Food and Drug Administration.
3. FDA. Labeling and Safety Communications for everolimus-containing products. U.S. Food and Drug Administration.
4. American Conference of Governmental Industrial Hygienists (ACGIH) and other clinical safety communications are not applicable; omitted.

DrugChatter Q&A for AFINITOR

Afinitor patent expiration?
Afinitor generic name date generiquee?
How to get afinitor disperz?
Afinitor loss of exclusivity?
Afinitor patent expiry date in spain?